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ABSTRACT
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To answer the clinical question: ‘what analgesic medicine shall I prescribe this patient with chronic low back pain to reduce their pain?
’.
The objectives are to determine the analgesic effects, safety, effect on function, and relative rank according to analgesic effect, safety
and effect on function of a single course of opioid analgesics, NSAIDs or paracetamol or combinations of these medicines.

Description of the condition
Low back pain (LBP) presents an enormous global health problem.
It is the leading cause of disability (GBD Collaborators 2017a),
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and fourth-leading cause of disease burden amongst non-communicable health conditions (GBD Collaborators 2017b). In the
preceding 20 years, the amount of disability caused by LBP has
remained stable; however the disease burden has increased. Recent-onset (acute) LBP has a favourable initial prognosis (Menezes
Costa 2012). However, only one-third of people are recovered
12 weeks from pain onset and this changes little at 12 months
from pain onset (Itz 2013). LBP persisting longer than 12 weeks
is termed chronic low back pain (Furlan 2015; Treede 2015).
Technically, pain in the low back area is a symptom. Nonetheless, the usual use of the term LBP is to describe the condition of
non-specific LBP (NSLBP). NSLBP is the most common form of
LBP, commonly stated to be 90% of all cases (Koes 2006), and is
so termed because there is no identifiable problem (in the back)
that is causing the LBP symptoms (Maher 2017). Much less common conditions for which there is an identifiable problem include
fracture, infection, malignancy (tumour), radiculopathy (sciatica
involving problematic nerve function), spinal stenosis (narrowing
of spinal openings) or inflammatory arthropathy (inflammatory
joint problems) (Downie 2013; Enthoven 2016a; Henschke 2008;
Koes 2006). The focus of this review is chronic non-specific LBP
(CLBP).

Description of the intervention
Medicines prescribed to reduce pain intensity (analgesic
medicines) are the most common form of treatment for CLBP
(Gore 2012; Hart 2015; Ivanova 2011). Analgesic medicines work
in various ways to reduce the intensity of pain but may also cause
unwanted harmful effects. Clinical decisions to recommend particular pain-relieving medicines involve a balance between the anticipated reduction in pain and the possibility of side effects. This is
particularly important when people have other relevant health conditions such as the inability to tolerate some medicines, or problems with kidney or liver function. Clinical use of these medicines
varies across healthcare settings and geographical areas and is
usually different to guideline recommendations (Amorin-Woods
2014; Bishop 2003; Cifuentes 2010; Gore 2012; Gouveia 2017;
Hart 2015; Hoffmann 2013; Ivanova 2011; Mafi 2013; Ndlovu
2014; Webster 2005; Webster 2007). In this review, we will focus on the three most commonly prescribed classes of analgesic
medicines: paracetamol (acetaminophen); non-steroidal anti-inflammatory drugs (NSAIDs); and opioid analgesics.

How the intervention might work
The human body creates its own natural opioid molecules (endogenous opioids), for a variety of functions. The nervous system contains receptors for these opioids on the exterior of cells
(Kieffer 2009). When opioid molecules bind to receptors, this
causes changes within the cells. Opioid analgesics, as they are

termed in this review, are medicines made synthetically that match
or are chemically similar to endogenous opioids. When taken,
opioid analgesics attach to the opioid receptors on nervous system cells, causing a reduction in perceived pain (Kieffer 2009;
Rachinger-Adam 2011). Opioids have other effects as well, depending on the location and type of the receptor. One common side effect from taking opioids is constipation, because the
medicine also binds to receptors in the digestive system and interferes with digestion (Rachinger-Adam 2011); other side effects
are that people taking opioids may develop tolerance (they require
larger doses for the same effect) or dependence on the medicine
(they experience withdrawal symptoms if a dose is missed), or both
(Deyo 2015).
NSAIDs and paracetamol interfere with the natural inflammatory processes in the body, in particular the production of chemicals called prostaglandins (Brune 2015). Prostaglandins are themselves involved in several processes. One of these is pain perception, which they contribute to by increasing inflammation. They
also contribute to blood-clotting processes and support the lining of the stomach (Brune 2015). An enzyme called cyclooxygenase (COX) helps to create prostaglandins. NSAIDs lessen the effect of COX type-1 (COX-1) and COX type-2 (COX-2), which
reduces prostaglandins and, in turn, reduces the perception of
pain. The unavoidable reduction in prostaglandins elsewhere (e.g.
the stomach) is associated with side effects (e.g. stomach ulcers)
(Brune 2015). Some NSAIDs selectively inhibit COX-2, which
is less present in the stomach: these ‘selective’ NSAIDs are associated with diminished digestive system side effects (Davies
2000; Sostres 2013; Whittle 2000). Both selective and non-selective NSAIDs have known cardiovascular risks (Baigent 2013;
McGettigan 2011).
Paracetamol also inhibits the COX-1 and COX-2 enzymes
(Graham 2013; Jozwiak-Bebenista 2014), particularly COX-2
(Graham 2013; Hinz 2008; Hinz 2012). Paracetamol is generally
a safe medicine to take. However, overdosing (exceeding the recommended daily dose) is associated with an increased risk of liver
problems and death (Daly 2008; Graham 2013; Sheen 2002).

Why it is important to do this review
There is uncertainty about the comparative effectiveness of most
analgesic medicines for CLBP. This is problematic given their wide
use (Gore 2012; Hart 2015; Ivanova 2011), side effects (Baigent
2013; Deyo 2015; Humphreys 2017; Martell 2007; McGettigan
2011; Shaheed 2016), and the variety of available formulations.
Evidence of comparative effectiveness - the analgesic effect and
safety of a medicine in comparison to other medicines that may
be prescribed for the same condition - is the information required
most by clinicians. This information is presently insufficiently described in the literature. Systematic reviews of these medicines typically include limited data on comparative effectiveness (Chaparro
2014; Chou 2017; Enthoven 2016b; Saragiotto 2016b), and
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focus on effects compared to placebo (Chaparro 2014; Chou
2007; Chung 2013; Enthoven 2016b; Furlan 2006; Furlan 2011;
Kuijpers 2011; Machado 2017; Shaheed 2016; White 2011a),
or aspects of clinical trial design (Furlan 2006; Furlan 2011).
While many factors influence prescribing decisions (Bhamb 2006;
Cabana 1999; Darlow 2012; Perrot 2008; Schers 2001), the lack
of evidence of comparative effectiveness for many analgesics means
that prescribing is less evidence-informed and more reliant on
other factors such as clinical experience and patient preferences.
Network meta-analysis (NMA) can provide the information on
comparative effectiveness that is needed to make informed clinical
decisions. NMA is a simultaneous comparison of all competing
treatments (Salanti 2012). The results of NMA are expressed as
the effect of a treatment, on a particular outcome, compared to
every other competing treatment. This review will provide a comprehensive evaluation of the comparative effectiveness of analgesic
medicines for CLBP and will express these data in formats that are
accessible to clinicians.

the network were included in a single mega-trial, there is an equal
likelihood that any one participant may be randomised to any of
those treatments (Salanti 2012). From a participant’s perspective,
transitivity means that if they were a participant in any one of the
trials in the network, they would have an equal chance of being a
participant in any of the other trials in the network.
The results from NMA may be portrayed in formats that are useful for clinical decision-making. The results for each treatment
are displayed in a league table, which may display results for two
outcomes (e.g. analgesic effect and safety). This is helpful for clinicians, because they can see the evidence for a treatment’s benefits alongside its risks. The league table displays all of the results,
which means that clinicians have all of the required information
in one place. These results can also be used to produce rankings of
the effect of treatments on a particular outcome (Dominici 1999;
Hoaglin 2011; Jansen 2011; Sutton 2008; van der Valk 2009).

OBJECTIVES
Description of network meta-analysis
Network meta-analysis (NMA) is an extension of pairwise metaanalysis that compares more than two treatments (Lu 2004). NMA
uses networks to represent the evidence base. Each competing
treatment is represented as a node (vertex) and each comparison
between treatments is represented by lines (edges) connecting the
treatments (Jansen 2011). As with pairwise meta-analysis, it is important that an NMA is conducted within a rigorous systematic
review process to ensure that all relevant information is included.
Information that is missing from the network, for example clinical trials of a particular treatment comparison, may lead to bias
in the results (Mills 2013). A network with no missing information will likely still contain a mix of solid and blank (or absent)
edges. Solid edges are termed ‘direct’ comparisons because these
have been compared in clinical trials. Absent edges are termed
‘indirect’ comparisons - there have been no clinical trials of these
comparisons (Bucher 1997; Jansen 2011).
NMA uses the ‘direct’ clinical trial data to ‘indirectly’ estimate
the effects for the missing comparisons (blank edges) (Caldwell
2005; Cipriani 2009; Jansen 2011; Jansen 2013; Mills 2013; Song
2003; Sutton 2008). In this way, NMA can be said to fill in the
gaps in the evidence base. This process involves fitting a single
statistical model to the network, which simultaneously combines
all the information from the clinical trials (the direct comparisons)
together with the information about the network structure (in
particular, the missing comparisons) (Efthimiou 2016; Krahn
2013; Salanti 2012).
The transitivity assumption underpins the validity of NMA. The
assumption holds when the characteristics of the participants and
trials included in the network are sufficiently similar across all
of the direct comparisons in the network (Jansen 2013). From a
researcher’s perspective, transitivity means that if all treatments in

To answer the clinical question: ‘what analgesic medicine shall I
prescribe this patient with chronic low back pain to reduce their
pain?’.
The objectives are to determine the analgesic effects, safety, effect
on function, and relative rank according to analgesic effect, safety
and effect on function of a single course of opioid analgesics,
NSAIDs or paracetamol or combinations of these medicines.

METHODS

Criteria for considering studies for this review

Types of studies
We will include conventional and enriched-design parallel group
RCTs and the first phase of cross-over RCTs. We will exclude cluster RCTs. Studies must compare at least two of the interventions
of interest.
Types of participants
We will include studies of people with chronic, non-specific LBP
defined as a primary area of pain between the twelfth rib and
gluteal fold, with or without associated leg pain, for which the
same episode has persisted for longer than three months (Furlan
2015; Treede 2015). We will exclude studies where subjects have
leg pain that meets the definition of sciatica used by Koes 2007 or
where low back pain is caused by pathological entities such as infection, neoplasm, metastasis, osteoporosis, inflammatory disease
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or fractures. We will include studies that include participants with
conditions other than CLBP (e.g. sciatica or ankylosing spondylitis) if separate data is reported for the CLBP participants or may
be obtained from study authors.

Types of interventions
We will include studies of analgesic medicines prescribed for the
intended purpose of reducing pain intensity for someone with
CLBP, defined as paracetamol (acetaminophen), NSAIDs and opioid analgesics. The interventions of interest are listed in Appendix
1 and include placebo and no treatment. Each medicine is a separate intervention (node) in the analysis. We will not combine
different medicines into the same node. The NMA will compare
every medicine to every other medicine. If we identify NSAIDs
or opioid analgesics that are inadvertently not listed in Appendix
1, we will consider them as eligible and we will include them in
the network after assessing their comparability with the pre-specified set of competing interventions. We will report the findings
for these interventions in the results and the conclusions of the
review.

We will include analgesic medicines delivered as mono or combination therapy (delivery of one or more agents at once for the
same intended therapeutic effect, in single or multiple formulations) via all systemic routes of administration. We will exclude
local therapeutic injections or topical applications and medicines
or dosages that are not currently licensed for human use. We will
include trials that contain non-pharmacological co-interventions
(intended by the trial investigators) in one or more of the intervention arms. Such co-interventions will be categorised as i) physical
therapies, or ii) psychological therapies, or iii) combinations of i)
and ii), for the evaluation of transitivity.
We assume that all analgesic medicines, defined herein, are directly comparable treatments. In other words, we assume that the
distribution of important characteristics (effect modifiers) is the
same across all treatment comparisons (Salanti 2012). The network diagram in Figure 1 displays all possible pairwise comparisons between opioid analgesics. We have not included NSAIDs
or paracetamol in this diagram for the sake of visual simplicity. All
medicines are categorised according to the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system.
The ATC codes are listed in Appendix 1.

Figure 1. All theoretically possible comparisons between the opioid analgesic interventions of interest.
NSAIDs and paracetamol are not included for the sake of simplicity.
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Network nodes will be further defined using the relevant licensed
dosing range (LDR) from the US Food and Drug Administration
(FDA), the Australian Therapeutic Goods Administration (TGA)
or the European Medicines Agency (EMA). For most medicines,
this is equivalent to the standard dosing range (SDR). For older
medicines, the SDR may be smaller than the LDR. The network
will include these doses as separate nodes. Thus, for drug A there
may be a single LDR node, whereas for drug B there may be a
’less than SDR’ node, an SDR node and a ’greater than SDR’
node. We will use the standard dosing range from the Australian
Medicines Handbook (AMH) and the Prescriber’s Digital Reference or MIMS when the medicine is not listed in the AMH (AMH
2017; MIMS 2017; PDR 2017). The placebo node is defined as
any drug intervention that does not contain an active ingredient.
The ’no treatment’ node is defined as any trial arm that contains
no investigator-intended treatment, and includes trial arms that
comprise continuation of usual care or being placed on a wait-list.
Types of outcome measures

Primary outcomes

The co-primary outcomes are pain and safety.
• Pain is defined as pain intensity, measured at the time point
closest to the end of treatment. Pain intensity may be measured
with a continuous self-report scale (e.g. visual analogue scale
(VAS) or numeric rating scale (NRS)), a rating scale within a
composite measure of pain (e.g. McGill Pain Questionnaire), or
an ordinal scale with greater than six levels (we will consider such
ordinal scales to exhibit continuous properties). We will not
exclude studies that use other measurement tools. We will
estimate the relative ranking of the competing interventions
according to their effect on pain intensity at the end of treatment.
• Safety is defined as the proportion of participants who
experience a serious adverse effect during the treatment period.
Adverse effects are described broadly as any of ‘adverse event’,
‘adverse drug reaction’, ‘side effect’, ‘toxic effect’ or ‘complication’
that are associated with the medicine under investigation. A
serious adverse effect is that which causes a reduction in dose or
cessation of treatment. No change or an increase in pain is not
considered an adverse effect. We will estimate the relative ranking
of the competing interventions according to their effect on safety.
We note that randomised controlled trials have limitations in the
evaluation of medicine safety, particularly enriched designs (Furlan
2011). The study size, duration of treatment, length of followup and inclusion criteria are usually not appropriate to detect rare
events or evaluate long-term adverse effects (Brewer 1999; Sills
1986; Sutton 2002). Data on adverse effects may be available from

multiple sources (Sutton 2002), including observational cohort
designs, which are not included in this review. The Cochrane
Back and Neck Group is currently conducting a review of harms
of opioids for chronic non-cancer pain (Furlan 2014), and other
reviews of harms of NSAIDs have been published (for example,
Baigent 2013).

Secondary outcomes

• Pain, defined as pain intensity, measured at 1-month post
randomisation, provided the individual study treatment is
complete. The outcome is otherwise defined as above.
• Functional ability, defined as low back specific function,
measured at end of treatment. Functional ability may be
measured with a continuous, self-report scale (e.g. Roland
Morris Disability Questionnaire (RMDQ) or Oswestry
Disability Index (ODI)), a rating scale within a composite
measure (e.g. SF-36), or an ordinal scale with greater than six
levels (we will consider such ordinal scales to exhibit continuous
properties). We will not exclude studies that use other
measurement tools. We will estimate the relative ranking of the
competing interventions according to their effect on functional
ability at the end of treatment.

Search methods for identification of studies

Electronic searches
We will search for all possible comparisons formed by the interventions of interest. We will search the following electronic databases
from inception to current.
• Cochrane Back and Neck Group’s Trials Register (through
CENTRAL).
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library, current issue.
• MEDLINE (Ovid) (1946 to current).
• Embase (Ovid) (1980 to current).
• CINAHL (EBSCO) (1982 to current).
• ClinicalTrials.gov (ClinicalTrials.gov/ct2/home).
• WHO International Clinical Trial Registry Platform
(WHO ICTRP) (apps.who.int/trialsearch/Default.aspx).
We have developed the search strategies specifically for this review,
using the recommended back pain search terms (Furlan 2015),
and specific terms for the interventions of interest and their combinations. The search strategy for MEDLINE is listed in Appendix
2.
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Searching other resources

Study methods

We will check the reference lists of eligible studies and previous
systematic reviews to identify additional studies. We will contact
the corresponding authors of the most recent systematic reviews on
opioid analgesics, NSAIDs and paracetamol to enquire if they are
aware of any additional studies in the area of their review. We will
search for the protocols and registrations of all included studies.

We will extract data on the trial design. This will include the
number, country and setting of trial sites, sample size and total
duration of the trial.

Data collection and analysis

Participants
We will extract data on the individual study sample. This will
include the diagnosis, duration of LBP episode, age, male/female
ratio and co-morbidities, including alternate sites of pain. We will
extract arm-level pain intensity at baseline (mean (SD)).
Interventions

Selection of studies
Two reviewers from a panel of six (MKB, SK, BMW, AM, NH,
CW) will independently screen identified studies for eligibility in
two independent stages: i) title and abstract; ii) full text. Review
authors will not be involved in the decision to include any study
with which they have been involved. The reviewers will resolve
disagreements through discussion, with arbitration by a third reviewer (JHM) if required. We will contact study authors up to
three times to obtain additional information to determine study
eligibility. We will place the study in ‘Studies awaiting assessment’
for this iteration of the review if no reply is received within six
weeks. We will obtain translations of articles written in languages
that cannot be read by the authors through colleagues or Cochrane
resources such as Task Exchange. We will summarise the search
process using a PRISMA flow diagram (Liberati 2009).

Data extraction and management
Two reviewers from a panel of six (MKB, BMW, MH, NOC,
NH, CW) will independently extract data from included studies.
Review authors will not extract data from any study in which
they have had any involvement. We will use standardised, piloted,
data extraction forms. Required data will be taken from previous
Cochrane or non-Cochrane Reviews (conducted by the authors)
when possible. We will scan these data for implausible values; and if
found we will refer to the original article. The colleagues providing
the translation of studies written in other languages will also extract
data from these studies. The reviewers will resolve disagreements
through discussion, with arbitration by a third reviewer (JHM) if
required.
We will contact study authors up to three times to request additional data. We will consider the data unobtainable for this iteration of the review if no reply is received within six weeks. We
will only extract data for the interventions of interest from multiarm studies of many interventions. We will preference published
over unpublished data in situations where data sources conflict,
because published data have been through peer review.

We will extract data on the interventions. This will include the
duration of the intervention, including duration of any washout,
run-in or titration period; dosage regimen, including titration; and
routes of administration and usage of rescue medication.
Outcomes
We will extract the type and dimensions of the scale or measure
used to assess pain or functional ability and the time from randomisation at which the end of treatment data were obtained in
the individual trials. We will extract the definition of ’adverse effect’ and ’serious adverse effect’ used in each study.
Results
We will extract the number of participants allocated to each intervention group and the proportion of adherence to the intervention, including the definition of adherence. We will extract the proportion of participants in each group who discontinued treatment
due to an adverse effect. We will extract from each trial the event
rates and descriptions of all reported adverse effects and serious
adverse effects. We will extract the outcome score (preferred) for
pain and functional ability or the change in outcome from baseline
and the accompanying measure of variance (or available statistic
to estimate these values) for each group at the time point closest
to the end of treatment. We will also extract these data for pain at
the time point closest to 1-month post-randomisation, provided
study treatment is complete. We will extract the between-group
differences in scores and the accompanying measure of variance if
group-level data are not available. We will select and extract data
from a single outcome measure, in studies with more than one relevant outcome measure for pain, in the following order: 100 mm
VAS; 10 cm VAS; 11-point NRS; rating scale for pain intensity
from a composite measure of pain; ordinal scale with more than
six levels. We will select and extract data from a single outcome
measure, in studies with more than one relevant outcome measure
for functional ability, in the following order: ODI; RMDQ; rating
scale for functional ability from a composite measure; ordinal scale
with more than six levels.
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Assessment of risk of bias in included studies
Two reviewers from a panel of six (MKB, CW, MH, NH, SK,
NOC) will independently appraise outcome-level risk of bias for
the domains of selection, performance, attrition, detection, reporting and other sources of bias, using the Cochrane ’Risk of
bias’ tool, version 5.1.0 (Higgins 2011), and recommendations of
Furlan 2015 (Table 1; Table 2). Review authors will not appraise
risk of bias for any study in which they have had any involvement.
We will pilot-test the ’Risk of bias’ assessment procedure on a small
number of articles. ’Risk of bias’ assessments will be taken from
previous Cochrane Reviews or from previous reviews conducted
by the authors when possible. We will add any missing outcomelevel assessments.
We will determine single outcome-level risk of bias ratings for each
study, using an adaptation of the criteria in Furukawa 2016 for the
GRADE evaluation. Outcomes are at low overall risk when three
or fewer domains are rated ‘unclear’ risk and no domains are rated
‘high’; moderate overall risk if a single domain is rated as ‘high’
risk of bias, or no domain is rated as ‘high’ risk but four or more
are rated as ‘unclear’; and high overall risk in all other instances.
The reviewers will resolve disagreements through discussion, with
arbitration by a third reviewer (JHM) if required.

Unit of analysis issues

Studies with multiple treatment groups (multi-arm trials)

We will fit the network meta-analysis models using multivariate
meta-analysis in Stata (Higgins 2012; StataCorp 2015; White
2009; White 2011b; White 2012; White 2015), which accounts
for the presence of multi-arm trials. We will combine intervention
arms from the same trial that are within the same licensed dosing
range, using the formulae in Table 7.7a of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).

Dealing with missing data
We will contact study authors to provide missing data. We will impute missing data that are required for meta-analysis (e.g. standard
deviations), if they are not obtainable for this iteration of the review, using previously published methods (Wan 2014), and those
described in Sections 7.7 and 16.1 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).

Assessment of heterogeneity
Measures of treatment effect

Relative treatment effects

We will convert all outcome data for pain and functional ability to
common 0 to 100 point scales (mean (SD)). We will estimate the
relative treatment effects of the competing interventions on pain
and functional ability using weighted mean differences (WMD),
with 95% confidence intervals (95% CIs); and on safety using
risk ratios (RRs), with 95% CIs. We will present the results from
NMA as WMDs (pain and functional ability) and RRs (safety),
with 95% CIs, for each intervention compared to the reference
(placebo).
We will interpret the meaningfulness of the effect of medicines on
pain using the threshold of 10 points on a 0 to 100 point scale
(Chou 2017). We will use the 95% CIs of the risk ratio for safety
to judge meaningfulness on this outcome.

Relative treatment ranking

We will obtain hierarchies (rankings) of the effect of all interventions on pain and on safety using two measures: the probability
to be at each possible rank; and the surface under the cumulative
ranking curve (SUCRA) (Salanti 2011). We will present these hierarchies using rankograms, cumulative probability plots and clustered ranking graphs (Chaimani 2013; Salanti 2011).

Assessment of heterogeneity within treatment comparisons

We will use clinical and methodological judgement to assess the
presence of clinical and methodological heterogeneity within each
pairwise comparison by comparing the trial and study population
characteristics across all eligible trials. A judgement of excessive
clinical or methodological heterogeneity within a particular pairwise comparison will prevent meta-analysis.

Assessment of transitivity across the network

Transitivity is the fundamental assumption underpinning the validity of network meta-analysis. It is a statistically untestable
assumption, relying on a subjective assessment of clinical and
methodological heterogeneity across the network. Transitivity assumes that there is no imbalance in the distribution of treatment
effect modifiers across each of the comparisons in the network
(Jansen 2013). Any imbalance threatens the transitivity assumption. We will use several methods to evaluate the transitivity assumption. We consider the following clinical and methodological
factors to be potential treatment effect modifiers, in the absence
of robust evidence to date for effect modification in LBP trials
(Saragiotto 2016a).
• Baseline pain intensity
• Intended co-interventions, categorised as i) physical
therapies ii) psychological therapies, iii) combinations of i) and ii)
• Sample size (Dechartres 2016)
• Enriched design

Paracetamol, NSAIDS and opioid analgesics for chronic low back pain: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

We will visually assess the distributions of these effect modifiers
across all treatment comparisons in the network, using weighted
network plots in Stata (Chaimani 2013; Salanti 2012). We anticipate that insufficient reporting of effect modifiers in individual studies and pairwise comparisons containing few studies will
make assessment of the distribution of effect modifiers difficult
(Cipriani 2013). We will interpret a clearly dissimilar distribution
of an effect modifier across trials as a threat to transitivity. We will
proceed with NMA in the case of minor dissimilarities; and explore the influence of the effect modifier on inconsistency/heterogeneity using network meta-regression or subgroup analyses (or
both). We will consider excluding network nodes in the case of
considerable dissimilarity and will consider not proceeding with
NMA if intransitivity persists.
An equivalent expression of transitivity is that treatments missing
from each trial in the network are missing at random (Lu 2006),
which implies that there is no preference for a particular (set of )
comparison treatment/s (Salanti 2012). We will calculate network
geometry metrics for diversity and co-occurrence, using EcoSim
Professional v1.2d (Entsminger 2014), to assess the presence of
comparator preference bias. We will interpret a probability of interspecific encounter (PIE) index less than 0.75 and a statistically
significant C-score (P < 0.10) as indicative of limited diversity and
likely co-occurrence, respectively (Hurlbert 1971; Salanti 2008).
We will construct network plots and weight the edges by the number of checkerboard units for each comparison if limited diversity
or likely co-occurrence are identified. We will manually scrutinise
comparisons with a large number of checkerboard units to determine whether this co-occurrence is justifiable (Salanti 2008). We
will exclude network nodes (treatments) forming comparisons for
which there is non-justifiable co-occurrence.

Assessment of reporting biases
We will assess small study effects in pairwise comparisons, using
contour enhanced funnel plots (Peters 2008), when there are at
least 10 studies available. Various factors contribute to the association between study effect size and funnel plot asymmetry. Contour-enhanced funnel plots assist interpretation of asymmetry that
is due to publication bias and not other factors, such as lesser
methodological quality. The contour lines imposed on the plot indicate levels of statistical significance. We will interpret an absence
of studies in areas of non-significance as suggestive of publication
bias for that pairwise comparison.

Data synthesis

Methods for direct treatment comparisons

We will perform pairwise random-effects meta-analyses in Stata or
Review Manager 5 for each direct comparison for which there are

at least two studies available (StataCorp 2015; Review Manager
2014).

Methods for indirect and mixed comparisons

We aim to perform network meta-analysis within a frequentist
framework in Stata (Higgins 2012; White 2009; White 2011b;
White 2012; White 2015). The multivariate meta-analysis models incorporate random effects for heterogeneity and for inconsistency. We will not stratify study inclusion to the analysis by risk
of bias.

Assessment of statistical heterogeneity

Assumptions when estimating the heterogeneity

We will assume that the heterogeneity variance is different for
each direct comparison in standard pairwise meta-analyses. We
will assume that the heterogeneity variance is the same across the
different comparisons in network meta-analysis.

Measures and tests for heterogeneity

We will test for the presence of statistical heterogeneity (variance
in true effects) within each pairwise comparison using the Q statistic, with alpha less than 0.10 as we anticipate a small number of
trials per comparison. We will calculate 95% prediction intervals
for the pooled effects and interpret prediction intervals spanning
greater than 15 points (on a 0 to 100 scale) on either side of the
pooled effect as indicative of important heterogeneity. We will
visually inspect the distribution of effect sizes in the forest plots
and calculate the I² value to indicate the proportion of observed
variance that is due to heterogeneity (Borenstein 2009). We will
interpret I² greater than 50% as indicative of important heterogeneity. We will use the heterogeneity variances from the NMA
models as measures of total network heterogeneity.

Assessment of statistical inconsistency
Assessment of inconsistency is only possible if there are closed loops
of evidence in the network (all comparisons have direct evidence).
We will rely on the assessment of transitivity to infer the presence
of inconsistency if there are no closed loops. Inconsistency may not
be detected for two reasons. Firstly, tests to detect inconsistency
have low power (Higgins 2012; Krahn 2013; Song 2012; Veroniki
2014). Secondly, heterogeneity and inconsistency are interwoven.
In situations where there is large heterogeneity, this may mask the
presence of inconsistency (Song 2012; Veroniki 2013; Veroniki
2014).
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Global approaches for evaluating consistency

We will evaluate consistency across the entire network using the
’design-by-treatment’ interaction model (Higgins 2012; White
2012); and infer the presence of inconsistency based on P < 0.10.

Local approaches for evaluating consistency

We will evaluate consistency in closed loops with the loop-specific
approach (Bucher 1997) and node-splitting (Dias 2010), using a
threshold of P < 0.10 for either approach.

Strategy for investigating the sources of inconsistency

We will employ a staged approach to investigate any significant
inconsistency that we encounter (Cipriani 2013; Salanti 2012).
In the first instance, we will check for data extraction errors in
the comparisons identified as inconsistent and those with important heterogeneity. Secondly, we will test whether the inconsistency may be explained using pre-specified covariates in network
meta-regression and subgroup analyses, provided sufficient studies are available. Lastly, if there remains significant unexplained
inconsistency, we will consider not proceeding with NMA. This
judgement will involve the clinical and methodological evaluation
of transitivity, the approaches to identify inconsistency and the
knowledge that small amounts of inconsistency may be due to
chance (Veroniki 2013).

Confidence in cumulative evidence
We will use the approach described by Salanti 2014 to construct
judgements of confidence in each of the pairwise effects derived
from NMA for pain and safety at end of treatment and confidence
in the ranking of treatments with respect to their effect on pain
and safety at end of treatment. We will likely use the Confidence
in Network Meta-Analysis (CINeMA) web application for this
process (ISPM 2017). We will consider the five GRADE domains:
risk of bias; indirectness; inconsistency; imprecision; and publication bias. Initial judgements of confidence will be ‘high’, because
the data come from randomised controlled trials, which are the
ideal study design for the research question. The procedures for
evaluation and downgrading of judgements differ slightly between
those for confidence in the pairwise effects and confidence in the
treatment rankings. These are described in Appendix 3.

Summary of findings
We will present ’Summary of findings’ tables for pain and safety
at end of treatment. The tables will be adapted from the current
template used in Cochrane Reviews and will contain, at a minimum, the treatment effect, assumed risk (for safety only), quality
of evidence (GRADE) and number of participants for each comparison in the network. An example ’Summary of findings’ table is

shown for a single comparison in Table 3. Development of methods for presentation of results of NMA is ongoing (e.g. Tan 2014;
Veroniki 2016), and we anticipate the summary of findings in
the finished review to incorporate these methodological advances
where appropriate.

Subgroup analysis and investigation of heterogeneity
We will perform network meta-regression or subgroup analyses
if sufficient studies are available, by investigating baseline pain
intensity, sample size and enriched design as possible sources of
inconsistency or heterogeneity. We may also investigate clinical or
methodological factors identified during the review process that
may threaten transitivity (Jansen 2012), as sources of inconsistency
or heterogeneity, or both. We will assume for each network metaregression model that the effects of the covariates are common
(the same) across all comparisons in the network (Chaimani 2012;
Dias 2013). This strong assumption is likely to make best use
of the available data (Dias 2013; Efthimiou 2016). We specify
the following assumptions about the direction of effect for each
covariate.
• Baseline pain intensity (continuous): increasing magnitudes
of the covariate increases the effect size between the intervention
and comparator (compared to trials in which the covariate is less).
• Sample size (continuous): increasing magnitudes of the
covariate reduces the effect size between the intervention and
comparator.
• Enriched design (binary): the presence of the covariate
increases the effect size for pain and decreases the effect size for
safety, between the intervention and comparator (compared to
trials in which the covariate is absent).
We plan to conduct a subgroup analysis if intended co-interventions are identified as threats to transitivity. We will group trials
that test drug interventions alone separately from trials that include intended co-interventions, provided that sufficient data are
available. We will assess small-study effects in pairwise comparisons using conventional funnel plots and across the entire network using comparison-adjusted funnel plots (Chaimani 2013).

Sensitivity analysis
We will conduct sensitivity analyses of pain and safety in which
studies at high risk of bias are excluded, provided that the original
network structure remains the same. We plan to investigate baseline pain intensity, sample size and enriched design in sensitivity
analyses if sufficient data are not available for network meta-regression or subgroup analysis. We will dichotomise baseline pain
intensity and sample size and exclude trials with baseline pain intensity higher than 70/100 (VAS) and sample size less than 50, respectively. We will also conduct sensitivity analyses of the analyses
for pain at end of treatment and safety if we impute missing data
for either of these outcomes.
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ADDITIONAL TABLES
Table 1. Sources of risk of bias
Bias Domain

Source of Bias

PossibleAnswers

Selection

(1) Was the method of randomization adequate?

Yes/No/Unsure

Selection

(2) Was the treatment allocation concealed?

Yes/No/Unsure

Performance

(3) Was the patient blinded to the intervention?

Yes/No/Unsure

Performance

(4) Was the care provider blinded to the intervention?

Yes/No/Unsure

Detection

(5) Was the outcome assessor blinded to the intervention? Yes/No/Unsure

Attrition

(6) Was the drop-out rate described and acceptable?

Attrition

(7) Were all randomized participants analyzed in the Yes/No/Unsure
group to which they were allocated?

Reporting

(8) Are reports of the study free of suggestion of selective Yes/No/Unsure
outcome reporting?

Selection

(9) Were the groups similar at baseline regarding the most Yes/No/Unsure
important prognostic indicators?

Performance

(10) Were cointerventions avoided or similar?

Yes/No/Unsure

Performance

(11) Was the compliance acceptable in all groups?

Yes/No/Unsure

Detection

(12) Was the timing of the outcome assessment similar Yes/No/Unsure
in all groups?

Yes/No/Unsure

Paracetamol, NSAIDS and opioid analgesics for chronic low back pain: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

Table 1. Sources of risk of bias

Other

(Continued)

(13) Are other sources of potential bias unlikely?

Yes/No/Unsure

Furlan 2015

Table 2. Criteria for a judgment of “yes” for the sources of risk of bias

1

A random (unpredictable) assignment sequence.
Examples of adequate methods are coin toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups)
, drawing of balls of different colours, drawing of ballots with the study group labels from a dark bag, computer-generated
random sequence, preordered sealed envelopes, sequentially-ordered vials, telephone call to a central office, and preordered list
of treatment assignments
Examples of inadequate methods are: alternation, birth date, social insurance/security number, date in which they are invited
to participate in the study, and hospital registration number

2

Assignment generated by an independent person not responsible for determining the eligibility of the patients.
This person has no information about the persons included in the trial and has no influence on the assignment sequence or on
the decision about eligibility of the patient

3

Index and control groups are indistinguishable for the patients or if the success of blinding was tested among the patients and
it was successful

4

Index and control groups are indistinguishable for the care providers or if the success of blinding was tested among the care
providers and it was successful

5

Adequacy of blinding should be assessed for each primary outcome separately. This item should be scored “yes” if the success of
blinding was tested among the outcome assessors and it was successful or:
- for patient-reported outcomes in which the patient is the outcome assessor (e.g. pain, disability): the blinding procedure is
adequate for outcome assessors if participant blinding is scored “yes”
- for outcome criteria assessed during scheduled visit and that supposes a contact between participants and outcome assessors
(e.g., clinical examination): the blinding procedure is adequate if patients are blinded, and
the treatment or adverse effects of the treatment cannot be noticed during clinical examination
- for outcome criteria that do not suppose a contact with participants (e.g., radiography, magnetic resonance imaging): the
blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be
noticed when assessing the main outcome
- for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between patients and care
providers (e.g., cointerventions, hospitalization length, treatment failure), in which the care
provider is the outcome assessor: the blinding procedure is adequate for outcome assessors if item “4” (caregivers) is scored “yes”
- for outcome criteria that are assessed from data of the medical forms: the blinding procedure is adequate if the treatment or
adverse effects of the treatment cannot be noticed on the extracted data

6

The number of participants who were included in the study but did not complete the observation period or were not included in
the analysis must be described and reasons given. If the percentage of withdrawals and drop-outs does not exceed 20% for shortterm follow-up and 30% for long-term follow-up and does not lead to substantial bias a “yes” is scored. (N.B. these percentages
are arbitrary, not supported by literature)

7

All randomized patients are reported/analyzed in the group they were allocated to by randomization for the most important
moments of effect measurement (minus missing values) irrespective of noncompliance and cointerventions
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Table 2. Criteria for a judgment of “yes” for the sources of risk of bias

(Continued)

8

All the results from all prespecified outcomes have been adequately reported in the published report of the trial. This information
is either obtained by comparing the protocol and the report, or in the absence of the protocol, assessing that the published
report includes enough information to make this judgment

9

Groups have to be similar at baseline regarding demographic factors, duration and severity of complaints, percentage of patients
with neurological symptoms, and value of main outcome measure(s)

10

If there were no cointerventions or they were similar between the index and control groups

11

The reviewer determines if the compliance with the interventions is acceptable, based on the reported intensity, duration,
number and frequency of sessions for both the index intervention and control intervention(s). For example, physiotherapy
treatment is usually administered for several sessions; therefore it is necessary to assess how many sessions each patient attended.
For single-session interventions (e.g. surgery), this item is irrelevant

12

Timing of outcome assessment should be identical for all intervention groups and for all primary outcome measures

13

Other types of biases.
- Industry-sponsored trials. The conflict of interest (COI) statement should explicitly state that the researchers have had full
possession of the trial process from planning to reporting without funders with potential COI having any possibility to interfere
in the process. If, for example, the statistical analyses have been done by a funder with a potential COI, usually “unsure” is
scored

Furlan 2015

Table 3. Summary of findings

Paracetamol, NSAIDs and opioid analgesics for chronic low back pain: network meta-analysis
Patient or population: non-specific chronic low back pain
Settings: primary and secondary care, (additional detail unknown at protocol stage)
Intervention: paracetamol, NSAIDs or opioid analgesics
Comparison: intervention A vs intervention B, of X possible comparisons (unknown at protocol stage)
Outcomes

Outcome type

Outcome measure

Comments

Pain

Continuous

Pain intensity on 0 to 100 mm VAS

Measured at end of treatment

Safety

Dichotomous

Proportion of participants that experience a serious adverse event during
treatment

GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
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Table 3. Summary of findings

(Continued)

Very low quality: we are very uncertain about the estimate.

APPENDICES

Appendix 1. Interventions of interest

Drug name

ATC code

morphine

N02AA01

morphine combinations

N02AA51

hydromorphone

N02AA03

oxymorphone

N02AA

nicomorphine

N02AA04

oxycodone

N02AA05

oxycodone and naloxone

N02AA55

oxycodone and paracetamol

N02AJ17

oxycodone and acetylsalicylic acid

N02AJ18

oxycodone and ibuprofen

N02AJ19

codeine

R05DA04

codeine, combinations excl. psycholeptics

N02AA59

codeine and paracetamol

N02AJ06

codeine and acetylsalicylic acid

N02AJ07

codeine and ibuprofen

N02AJ08

codeine and other non-opioid analgesics

N02AJ09

Notes

where these are NSAIDs, as defined herein, or Paracetamol

where these are NSAIDs, as defined herein, or Paracetamol
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(Continued)

dihydrocodeine

N02AA08

dihydrocodeine combinations

N02AA58

dihydrocodeine and paracetamol

N02AJ01

dihydrocodeine and acetylsalicylic acid

N02AJ02

dihydrocodeine and other non-opioid anal- N02AJ03
gesics
papaveretum

N02AA10

buprenorphine

N02AE01

tilidine

N02AX01

dezocine

N02AX03

meptazinol

N02AX05

tapentadol

N02AX06

tramadol

N02AX02

tramadol and paracetamol

N02AJ13

tramadol and dexketoprofen

N02AJ14

tramadol and other non-opioid analgesics

N02AJ15

butaphornal

N02AF01

nalbuphine

N02AF02

ketobemidone

N02AB01

pethidine

N02AB02

pethidine, combinations excl. psycholep- N02AB52
tics
fentanyl

N02AB03

dextromoromide

N02AC01

piritramide

N02AC03

where these are combinations with NSAIDs, as defined herein, or Paracetamol

where these are NSAIDs, as defined herein, or Paracetamol

where these are NSAIDs, as defined herein, or Paracetamol

where these are NSAIDs, as defined herein, or Paracetamol
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(Continued)

dextropropoxyphene

N02AC04

bezitramide

N02AC05

methadone

N07BC02

methadone, combinations excl. psycholep- N02AC52
tics

where these are NSAIDs, as defined herein, or Paracetamol

dextropropoxyphene, combinations excl. N02AC54
psycholeptics

where these are NSAIDs, as defined herein, or Paracetamol

pentazocine

N02AD01

phenazocine

N02AD02

phenylbutazone

M01AA01

mofebutazone

M01AA02

oxyphenbutazone

M01AA03

piroxicam

M01AC01

lornoxicam

M01AC02

meloxicam

M01AC06

ibuprofen

M01AE01

naproxen

M01AE02

ketoprofen

M01AE03

fenoprofen

M01AE04

flurbiprofen

M01AE09

tiaprofenic acid

M01AE11

oxaprozin

M01AE12

dexibruprofen

M01AE14

dexketoprofen

M01AE17

mefenamic acid

M01AG01
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(Continued)

tolfenamic acid

M01AG02

meclofenamic acid

M01AG04

indomethacin

M01AB01

sulindac

M01AB02

tolmetin

M01AB03

zomepirac

M01AB04

diclofenac

M01AB05

alclofenac

M01AB06

etodolac

M01AB08

ketorolac

M01AB15

aceclofenac

M01AB16

bufexamac

M01AB17

celecoxib

M01AH01

valdecoxib

M01AH03

parecoxib

M01AH04

etoricoxib

M01AH05

nabumetone

M01AX01

glucosamine

M01AX05

GAG polysulfate

M01AX12

nimesulide

M01AX17

chondroitin sulphate

M01AX25

paracetamol (acetaminophen)

N02BE01

acetylsalicylic acid (aspirin)

N02BA01

acetylsalicylic acid, combinations excl. psy- M01BA03
choleptics

where these are NSAIDs, as defined herein, or Paracetamol
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Appendix 2. Search strategies
Search Strategy for MEDLINE (Ovid):
Part A: Generic search for randomized controlled trials
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. comparative study.pt.
4. clinical trial.pt.
5. random*.ab,ti.
6. placebo.ab,ti.
7. drug therapy.fs.
8. trial.ab,ti.
9. groups.ab,ti.
10. or/1-9
11. (animals not (humans and animals)).sh.
12. 10 not 11
Part B: Specific search for low back, sacrum and coccyx problems
13. dorsalgia.ti,ab.
14. exp Back Pain/
15. backache.ti,ab.
16. ((lumb* or back) adj pain).ti,ab.
17. coccydynia.ti,ab.
18. sciatica.ti,ab.
19. spondylosis.ti,ab.
20. lumbago.ti,ab.
21. or/13-20
Part C: Specific search for other spinal disorders
22. Coccyx.sh
23. Lumbar Vertebrae.sh
24. Intervertebral disc.sh
25. Sacrum.sh
26. Intervertebral disc degeneration.sh
27. (disc adj degenerat*).ti,ab.
28. (disc adj prolapse*).ti,ab.
29. (disc adj herniat*).ti,ab.
30. spinal fusion.sh.
31. (facet adj joint*).ti,ab.
32. Intervertebral Disc Displacement.sh.
33. postlaminectomy.ti,ab.
34. or/22-33
Part D: Specific search for interventions of interest
35. morphine.sh or morphine.tw,kf.
36. hydromorphone.sh or hydromorphone.tw,kf.
37. oxycodone.sh or oxycodone.tw,kf.
38. oxymorphone.sh or oxymorphone.tw,kf.
39. nicomorphine.tw,kf.
40. codeine.sh or codeine.tw,kf.
41. exp naloxone/ or naloxone.tw,kf.
42. dihydrocodeine.tw,kf.
43. papaveratum.tw,kf.
44. buprenorphine.sh or buprenorphine.tw,kf.
45. tilidine.sh or tilidine.tw,kf.
46. dezocine.tw,kf.
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47. meptazinol.sh or meptazinol.tw,kf.
48. tapentadol.tw,kf.
49. tramadol.sh or tramadol.tw,kf.
50. butaphornal.tw,kf.
51. nalbuphine.sh or nalbuphine.tw,kf.
52. ketobemidone.tw,kf.
53. meperidine.sh or meperidine.tw,kf. or pethidine.tw,kf.
54. fentanyl.sh or fentanyl.tw,kf.
55. dextromoramide.sh or dextromoramide.tw,kf.
56. piritramide.sh or piritramide.tw,kf.
57. dextropropoxyphene.sh or dextropropoxyphene.tw,kf.
58. bezitramide.tw,kf.
59. methadone.sh or methadone.tw,kf.
60. pentazocine.sh or pentazocine.tw,kf.
61. phenazocine.sh or phenazocine.tw,kf.
62. phenylbutazone.sh or phenylbutazone.tw,kf.
63. mofebutazone.tw,kf.
64. oxyphenbutazone.sh or oxyphenbutazone.tw,kf.
65. meloxicam.tw,kf.
66. piroxicam.sh or piroxicam.tw,kf.
67. lornoxicam.tw,kf.
68. ibuprofen.sh or ibuprofen.tw,kf.
69. naproxen.sh or naproxen.tw,kf.
70. ketoprofen.sh or ketoprofen.tw,kf.
71. fenoprofen.sh or fenoprofen.tw,kf.
72. flurbiprofen.sh or flurbiprofen.tw,kf.
73. tiaprofenic acid.tw,kf.
74. oxaprozin.tw,kf.
75. dexibuprofen.tw,kf.
76. dexketoprofen.tw,kf.
77. mefenamic acid.sh or mefenamic acid.tw,kf.
78. tolfenamic acid.tw,kf.
79. meclofenamic acid.sh or meclofenamic acid.tw,kf.
80. exp indomethacin/ or indometacin.tw,kf.
81. sulindac.sh or sulindac.tw,kf.
82. tolmetin.sh or tolmetin.tw,kf.
83. zomepirac.tw,kf.
84. diclofenac.sh or diclofenac.tw,kf.
85. alclofenac.tw,kf.
86. etodolac.sh or etodolac.tw,kf.
87. aceclofenac.tw,kf.
88. bufexamac.sh or bufexamac.tw,kf.
89. celecoxib.sh or celecoxib.tw,kf.
90. valdecoxib.tw,kf.
91. etoricoxib.tw,kf.
92. nabumetone.tw,kf.
93. exp glucosamine/ or glucosamine.tw,kf.
94. glucosaminoglycan polysulfate.tw,kf.
95. nimesulide.tw,kf.
96. chondroitin sulfate.tw,kf.
97. acetaminophen.sh or acetaminophen.tw,kf. or paracetamol.tw,kf.
98. aspirin.sh or aspirin.tw,kf. or acetylsalicylic acid.tw,kf.
99. or/35-98 (all interventions of interest)
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Results
100. 21 or 34 (all back pain)
101. 99 and 100 (all back pain and all interventions of interest)
102. 12 and 101 (all RCTs of interventions of interest in back pain)

Appendix 3. The GRADE approach to evidence synthesis
The quality of evidence will be categorized as follows:
• High (
• Moderate (

): further research is very unlikely to change the confidence in the estimate of effect.
): further research is likely to have an important impact in the confidence in the estimate of effect.

): further research is very likely to have an important impact on our confidence in the estimate of effect and is
• Low (
likely to change the estimate.
• Very Low (

): any estimate of effect is very uncertain.

Initial judgements of confidence will be ‘high’, because the data come from randomised controlled trials. We will consider the five
GRADE domains: risk of bias, indirectness, inconsistency, imprecision and publication bias. The evidence available under each of these
domains will be graded according to slightly different procedures for confidence in the pairwise effects and confidence in the treatment
rankings.

Judgement of confidence in the pairwise effects
1) Risk of bias. We will rate each direct comparison as at low, moderate or high risk of bias, assigning scores of 0, −1 and −2, respectively.
We will consider direct comparisons at high risk of bias when > 25% of participants in the comparison are from studies at high overall
risk of bias, low risk when > 50% of participants are from studies at low overall risk and moderate risk in all other instances. We will
use the percentage contributions of all direct comparisons to each pairwise effect (from the contribution matrix) to construct weighted
averages of these scores. Then we will base judgements of the confidence to be placed in each pairwise effect on a weighted average of
the risk of bias of direct comparisons feeding into it. We will downgrade one level for −1.5 < score < −0.5 and two levels for scores <
−1.51, although this may change in practice if there is clear imbalance in the contribution of evidence that would render such action
inappropriate.
2) Indirectness. We will evaluate the populations, interventions and outcomes in the studies contributing to each direct comparison
for congruence with those specified for this review. We will consider downgrading a pairwise effect one level for indirectness if direct
comparisons with important imbalances in populations, treatments or outcomes contribute the majority of information to it. In
addition, we will downgrade all comparisons one additional level if there were concerns over the transitivity assumption identified prior
to the analysis.
3) Inconsistency. We will evaluate each direct comparison for consistency in the direction and magnitude of the effect sizes from
individual trials, considering the width of the prediction interval and magnitude of the heterogeneity parameter. We will downgrade
direct comparisons one level if important heterogeneity is identified. Additionally, we will downgrade one level any direct comparisons
that are implicated in loops with important incoherence or where there is a discrepancy between direct and indirect evidence.
4) Imprecision. We will downgrade due to imprecision based on consideration of the width of the confidence intervals. We will
downgrade one level when these span either the null or the threshold for a clinically meaningful effect on pain intensity (10 points on a
0 to 100 scale (Chou 2017)) and two levels when the interval spans both. We will not consider sample sizes as there are no established
criteria for this evaluation in the NMA context (Salanti 2014).
5) Publication bias. We will consider the likelihood of publication bias for each direct comparison, using both epidemiological judgement
and the contour-enhanced funnel plots. We will downgrade one level if we consider it likely that studies have been conducted and not
published.

Judgement of confidence in the treatment rankings
The difference between the judgement of confidence in the treatment rankings and that for the pairwise effect sizes is that this is a
single judgement for the ranking evidence as a whole.
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1) Risk of bias. We will use the scores of 0, −1, or −2 as previously for the judgements of overall risk of bias for each direct comparison
and construct a weighted average for the entire network using the percentage contributions of each direct comparison to the entire
network. We will downgrade one level for −1.5 < score < −0.5 and two levels for scores < −1.51, although this may change in practice
if there is clear imbalance in the contribution of evidence that would render such action inappropriate.
2) Indirectness. We will use the above evaluation of congruence between study populations, interventions and outcomes. We will
evaluate the contribution to the entire network by comparisons that are judged to exhibit indirectness. We will consider downgrading
one level if there is an important contribution from one/more of these comparisons. In addition, we will downgrade all comparisons
one additional level if there were concerns over the transitivity assumption identified prior to the analysis.
3) Inconsistency. We will consider the magnitude of the heterogeneity parameter from the NMA model and the result of the Chi² test
for global inconsistency, acknowledging that we may fail to detect important global inconsistency due to the low power of such a test
and the presence of large heterogeneity (Higgins 2012; Krahn 2013; Song 2012; Veroniki 2013; Veroniki 2014). We will downgrade
one level if either heterogeneity or inconsistency are present and two levels if both are present.
4) Imprecision. Imprecision in ranking may be conceptualised as uncertainty in the probability that a treatment achieves a certain rank
(Salanti 2014). We will evaluate the precision of the treatment rankings by examining the SUCRA values that are used to calculate
these probabilities. We will deem rankings imprecise when there are similar probabilities for two/more treatment to be ranked at the
same level. We will downgrade one level in this situation.
5) Publication bias. We will evaluate the likelihood of publication bias across the network, using epidemiological judgement, evidence
of publication bias in direct comparisons and the comparison-adjusted funnel plot, acknowledging that plot asymmetry may due to
real factors other than publication bias (Salanti 2014). We will downgrade one level if there is evidence of publication bias or small
study effects.
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